ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i6.901ppharm-162Research ArticleВ ПРАКТИКУ ПЕДИАТРАFor Pediatricians' PracticeОПЫТ ИСПОЛЬЗОВАНИЯ ПРЕПАРАТА ТОЦИЛИЗУМАБ У МАЛЬЧИКА С СИСТЕМНОЙ ФОРМОЙ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТАEXPERIENCE OF USING DRUG TOCILIZUMAB IN A BOY WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITISАфонинаЕ. Ю.ZholobovaE. S.

доктор медицинских наук, профессор кафедры детских болезней Первого МГМУ им. И.М. Сеченова

PhD, Professor at the department of childhood diseases at the First Sechenov MSMU

neonatepearl@yandex.ruЖолобоваЕ. С.ZholobovaE. S.Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Sechenov Moscow State Medical UniversityRussian Federation201302122013106Педиатрическая фармакология8284Copyright © Афонина Е.Ю., Жолобова Е.С., 20132013Афонина Е.Ю., Жолобова Е.С.Zholobova E.S., Zholobova E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/162

The article presents a case of complicated diagnostics of systemic juvenile idiopathic (rheumatoid) arthritis (JIA) starting with a fever of unclear genesis. Efficacy of interleukin 6 inhibitor tocilizumab for treating the systemic JIA resistant to glucocorticosteroid and methotrexate therapy is shown.

ювенильный идиопатический артритсистемная форма ЮИАбиологическая терапияингибитор IL 6тоцилизумабдетиjuvenile idiopathic arthritissystemic JIAbiological therapyIL 6 inhibitortocilizumabchildrenReferencesАлексеева Е. И. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Под общ. ред. А. А. Баранова. М.: ВЕДИ. 2007. 360 с.Alekseeva E. I. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Pod obshch. red. A.A. Baranova [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Features, Diagnosis and Treatment Algorithms. Edited by A.A. Baranov]. Moscow, VEDI, 2007. 360 p.Жолобова Е. С., Шахбазян И. Е., Улыбина О. В. Ювенильный ревматоидный артрит. Руководство по детской ревматологии. Под редакцией Н. А. Геппе, Н. С. Подчерняевой, Г. А. Лыскиной. М.: ГЭОТАР-Медиа. 2011. С. 162–245.Zholobova E. S., Shakhbazyan I. E., Ulybina O. V. Yuvenil'nyi revmatoidnyi artrit. Rukovodstvo po detskoi revmatologii. Pod redaktsiei N. A. Geppe, N. S. Podchernyaevoi, G. A. Lyskinoi [Juvenile Rheumatoid Arthritis. Guidelines for Pediatric Rheumatologist. Edited by N. A. Geppe, N. S. Podchernyaeva, G. A. Lyskina]. Moscow, GEOTAR-Media, 2011. pp. 162–245.Beukelman T., Patkar N. M., Saag K. G. et al. 2011 American College of Rheumatology. Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Research. April 2011; 63 (4): 465–482.Beukelman T., Patkar N. M., Saag K. G. et al. 2011 American College of Rheumatology. Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Research. April 2011; 63 (4): 465–482.Бзарова Т. М., Алексеева Е. И., Петеркова В. А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным идиопатическим артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Bzarova T. M., Alekseeva E. I., Peterkova V. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 720.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.Alexeeva E., Denisova R., Valieva S., Bzarova T., Isayeva K., Sleptsova T., Mitenko E. Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2011; 9 (Suppl. 1): 202.Alexeeva E., Denisova R., Valieva S., Bzarova T., Isayeva K., Sleptsova T., Mitenko E. Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 202.De Benedetti F., Brunner H. I., Ruperto N., Kenwright A. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012; 367 (25): 2385–2395.De Benedetti F., Brunner H. I., Ruperto N., Kenwright A. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367 (25): 2385–2395.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 719.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 719.Russo R., Katsicas M. Tocilizumab in jia patients who have inadequate response to anti-tumour necrosis factor therapy. Pediatr Rheumatol Online J. 2011; 9 (Suppl. 1): 186.Russo R., Katsicas M. Tocilizumab in jia patients who have inadequate response to anti-tumour necrosis factor therapy. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 186.Sawhney S., Aggarwal M. Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India. Pediatr Rheumatol Online J. 2012; 10 (Suppl. 1): 49.Sawhney S., Aggarwal M. Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India. Pediatr. Rheumatol. Online J. 2012; 10 (Suppl. 1): 49.Smolen J. S., Schoels M. M., Nishimoto N. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin n-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013; 72 (4): 482–492.Smolen J. S., Schoels M. M., Nishimoto N. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin n-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 2013; 72 (4): 482–492.Yokota S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 715.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.Yokota S., Tanaka T., Kishimot T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012; 4 (6): 387–397.Yokota S., Tanaka T., Kishimot T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther. Adv. Musculoskelet Dis. 2012; 4 (6): 387–397.

The authors declare that there are no conflicts of interest present.